Pancreatic Cancer Pill Doubles Patient Survival Time

A new pill targeting the KRAS mutation doubles survival time in pancreatic cancer patients, marking the biggest treatment breakthrough ever for one of the world's deadliest cancers.

After 25 years of research and $17 million in funding, scientists are finally seeing progress on multiple fronts at once.